IFM Investors Pty Ltd Purchases 9,201 Shares of Eli Lilly and Company (NYSE:LLY)

IFM Investors Pty Ltd boosted its stake in Eli Lilly and Company (NYSE:LLYGet Rating) by 7.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 137,974 shares of the company’s stock after acquiring an additional 9,201 shares during the quarter. Eli Lilly and accounts for 0.8% of IFM Investors Pty Ltd’s portfolio, making the stock its 21st largest position. IFM Investors Pty Ltd’s holdings in Eli Lilly and were worth $44,735,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the stock. Marcum Wealth LLC increased its stake in Eli Lilly and by 9.1% in the 2nd quarter. Marcum Wealth LLC now owns 4,101 shares of the company’s stock valued at $1,330,000 after buying an additional 343 shares during the last quarter. Orion Portfolio Solutions LLC increased its stake in shares of Eli Lilly and by 3.5% during the 2nd quarter. Orion Portfolio Solutions LLC now owns 5,570 shares of the company’s stock worth $1,806,000 after purchasing an additional 186 shares during the last quarter. Steigerwald Gordon & Koch Inc. increased its stake in shares of Eli Lilly and by 19.0% during the 2nd quarter. Steigerwald Gordon & Koch Inc. now owns 3,769 shares of the company’s stock worth $1,222,000 after purchasing an additional 603 shares during the last quarter. Adviser Investments LLC increased its stake in shares of Eli Lilly and by 12.2% during the 2nd quarter. Adviser Investments LLC now owns 1,465 shares of the company’s stock worth $475,000 after purchasing an additional 159 shares during the last quarter. Finally, Atalanta Sosnoff Capital LLC increased its stake in shares of Eli Lilly and by 49.8% during the 2nd quarter. Atalanta Sosnoff Capital LLC now owns 232,365 shares of the company’s stock worth $75,339,000 after purchasing an additional 77,298 shares during the last quarter. 82.45% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently commented on LLY shares. Barclays upped their price target on shares of Eli Lilly and from $333.00 to $355.00 and gave the company an “overweight” rating in a research note on Thursday, July 7th. JPMorgan Chase & Co. boosted their price objective on shares of Eli Lilly and from $340.00 to $355.00 in a report on Wednesday, June 1st. Citigroup boosted their price objective on shares of Eli Lilly and from $285.00 to $370.00 in a report on Thursday, August 25th. StockNews.com raised shares of Eli Lilly and from a “buy” rating to a “strong-buy” rating in a report on Wednesday, September 14th. Finally, BMO Capital Markets boosted their price objective on shares of Eli Lilly and from $369.00 to $396.00 and gave the company an “outperform” rating in a report on Tuesday, September 6th. Three investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Eli Lilly and currently has an average rating of “Moderate Buy” and an average target price of $332.19.

Eli Lilly and Trading Up 5.0 %

NYSE LLY traded up $14.69 on Thursday, hitting $311.17. The company’s stock had a trading volume of 273,526 shares, compared to its average volume of 2,217,114. The company has a quick ratio of 0.85, a current ratio of 1.10 and a debt-to-equity ratio of 1.70. Eli Lilly and Company has a 1-year low of $220.20 and a 1-year high of $335.33. The company’s 50-day moving average is $314.65 and its 200 day moving average is $304.11. The firm has a market cap of $295.66 billion, a PE ratio of 47.29, a PEG ratio of 1.95 and a beta of 0.38.

Eli Lilly and (NYSE:LLYGet Rating) last announced its quarterly earnings results on Thursday, August 4th. The company reported $1.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.86 by ($0.61). Eli Lilly and had a net margin of 19.58% and a return on equity of 85.58%. The business had revenue of $6.49 billion during the quarter, compared to analyst estimates of $6.85 billion. During the same quarter last year, the company posted $1.87 earnings per share. The company’s revenue was down 3.7% compared to the same quarter last year. As a group, analysts predict that Eli Lilly and Company will post 7.97 earnings per share for the current fiscal year.

Eli Lilly and Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, September 9th. Investors of record on Monday, August 15th were paid a dividend of $0.98 per share. This represents a $3.92 annualized dividend and a yield of 1.26%. The ex-dividend date of this dividend was Friday, August 12th. Eli Lilly and’s dividend payout ratio is presently 62.52%.

Insider Transactions at Eli Lilly and

In other news, Director Jackson P. Tai purchased 656 shares of the company’s stock in a transaction that occurred on Friday, August 12th. The stock was purchased at an average cost of $304.19 per share, for a total transaction of $199,548.64. Following the completion of the transaction, the director now owns 62,857 shares of the company’s stock, valued at $19,120,470.83. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Eli Lilly and news, Director Jackson P. Tai acquired 656 shares of the firm’s stock in a transaction that occurred on Friday, August 12th. The stock was acquired at an average cost of $304.19 per share, with a total value of $199,548.64. Following the acquisition, the director now directly owns 62,857 shares of the company’s stock, valued at approximately $19,120,470.83. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 215,000 shares of the firm’s stock in a transaction that occurred on Friday, June 24th. The stock was sold at an average price of $324.31, for a total transaction of $69,726,650.00. Following the sale, the insider now directly owns 104,203,810 shares of the company’s stock, valued at approximately $33,794,337,621.10. The disclosure for this sale can be found here. Insiders have sold 543,125 shares of company stock valued at $178,307,801 in the last three months. 0.12% of the stock is currently owned by company insiders.

Eli Lilly and Company Profile

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYGet Rating).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.